147 related articles for article (PubMed ID: 11175728)
1. Antigen-specific downregulation of T cells by doxorubicin delivered through a recombinant MHC II--peptide chimera.
Casares S; Stan AC; Bona CA; Brumeanu TD
Nat Biotechnol; 2001 Feb; 19(2):142-7. PubMed ID: 11175728
[TBL] [Abstract][Full Text] [Related]
2. Induction of thymocyte deletion by purified single peptide/major histocompatibility complex ligands.
Lesage S; Charron J; Winslow G; Hugo P
J Immunol; 1997 Sep; 159(5):2078-81. PubMed ID: 9278291
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation.
Casares S; Zong CS; Radu DL; Miller A; Bona CA; Brumeanu TD
J Exp Med; 1999 Aug; 190(4):543-53. PubMed ID: 10449525
[TBL] [Abstract][Full Text] [Related]
4. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
Bot A; Casares S; Bot S; von Boehmer H; Bona C
J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
[TBL] [Abstract][Full Text] [Related]
5. Presentation of a viral peptide assembled on the carbohydrate moieties of immunoglobulin does not require processing.
Brumeanu TD; Casares S; Dehazya P; Bot S; Bona CA
Eur J Immunol; 1997 Sep; 27(9):2408-16. PubMed ID: 9341787
[TBL] [Abstract][Full Text] [Related]
6. Viral peptide specific induction of MHC class II expression by murine T cell clones.
Thomas DB; Smith CA; Graham CM
J Immunol; 1996 Sep; 157(6):2386-94. PubMed ID: 8805637
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera.
Casares S; Hurtado A; McEvoy RC; Sarukhan A; von Boehmer H; Brumeanu TD
Nat Immunol; 2002 Apr; 3(4):383-91. PubMed ID: 11862219
[TBL] [Abstract][Full Text] [Related]
8. Maturation and function of mouse T-cells with a transgenic TCR positively selected by highly disparate xenogeneic porcine MHC.
Zhao Y; Rodriguez-Barbosa JI; Zhao G; Shaffer J; Arn JS; Sykes M
Cell Mol Biol (Noisy-le-grand); 2001 Feb; 47(1):217-28. PubMed ID: 11292257
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of generation and persistence on membrane class II molecules of a viral peptide expressed on foreign and self proteins.
Bot A; Bot S; Antohi S; Karjalainen K; Bona C
J Immunol; 1996 Oct; 157(8):3436-42. PubMed ID: 8871642
[TBL] [Abstract][Full Text] [Related]
10. A peptide-major histocompatibility complex II chimera favors survival of pancreatic beta-islets grafted in type 1 diabetic mice.
Casares S; Lin M; Zhang N; Teijaro JR; Stoica C; McEvoy R; Farber DL; Bona C; Brumeanu TD
Transplantation; 2008 Jun; 85(12):1717-25. PubMed ID: 18580462
[TBL] [Abstract][Full Text] [Related]
11. Soluble MHC II-peptide complexes induce antigen-specific apoptosis in T cells.
Nag B; Kendrick T; Arimilli S; Yu SC; Sriram S
Cell Immunol; 1996 May; 170(1):25-33. PubMed ID: 8660796
[TBL] [Abstract][Full Text] [Related]
12. How the T cell repertoire becomes peptide and MHC specific.
Huseby ES; White J; Crawford F; Vass T; Becker D; Pinilla C; Marrack P; Kappler JW
Cell; 2005 Jul; 122(2):247-60. PubMed ID: 16051149
[TBL] [Abstract][Full Text] [Related]
13. Induction of central T cell tolerance: recombinant antibodies deliver peptides for deletion of antigen-specific (CD4+)8+ thymocytes.
Schjetne KW; Thommesen JE; Fredriksen AB; Lunde E; Sandlie I; Bogen B
Eur J Immunol; 2005 Nov; 35(11):3142-52. PubMed ID: 16184515
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of an in vitro CD4+ T cell alloresponse using altered peptide ligands.
Daniel C; Grakoui A; Allen PM
J Immunol; 1998 Apr; 160(7):3244-50. PubMed ID: 9531280
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes.
Preda-Pais A; Stan AC; Casares S; Bona C; Brumeanu TD
J Autoimmun; 2005 Aug; 25(1):21-32. PubMed ID: 16005609
[TBL] [Abstract][Full Text] [Related]
16. The orientation of a T cell receptor to its MHC class II:peptide ligands.
Hong SC; Sant'Angelo DB; Dittel BN; Medzhitov R; Yoon ST; Waterbury PG; Janeway CA
J Immunol; 1997 Nov; 159(9):4395-402. PubMed ID: 9379037
[TBL] [Abstract][Full Text] [Related]
17. A subset of splenic macrophages process and present native antigen to naive antigen-specific CD4+ T-cells from mice transgenic for an alpha beta T-cell receptor.
Askew D; Gatewood J; Olivas E; Havenith K; Walker WS
Cell Immunol; 1995 Nov; 166(1):62-70. PubMed ID: 7585982
[TBL] [Abstract][Full Text] [Related]
18. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
19. Engineering and characterization of a murine MHC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope.
Casares S; Bona CA; Brumeanu TD
Protein Eng; 1997 Nov; 10(11):1295-301. PubMed ID: 9514118
[TBL] [Abstract][Full Text] [Related]
20. Production of soluble MHC class II proteins with covalently bound single peptides.
Kozono H; White J; Clements J; Marrack P; Kappler J
Nature; 1994 May; 369(6476):151-4. PubMed ID: 8177320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
